LSD instead of 25I-NBOMe: The revival of LSD? A case report

Bodeau, S., Bennis, Y., Régnaut, O., Fabresse, N., Richeval, C., Humbert, L., ... & Lemaire-Hurtel, A. S. | Toxicologie Analytique et Clinique | 27 February 2017

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects

Vizeli, P., Schmid, Y., Prestin, K., zu Schwabedissen, H. E. M., & Liechti, M. E. | European Neuropsychopharmacology | 20 January 2017

Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens

Halberstadt, A. L. | Current Topics in Behavioral Neurosciences | 18 January 2017

Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015

Heise, C. W., & Brooks, D. E. | Journal of medical toxicology | 28 November 2016

A Case of 3,4-Dimethoxyamphetamine (3,4-DMA) and 3,4 Methylendioxymethamphetamine (MDMA) Toxicity with Possible Metabolic Interaction

Darracq, M. A., Thornton, S. L., Minns, A. B., & Gerona, R. R. | Journal of Psychoactive Drugs | 16 September 2016

Multisystem Organ Failure and Death Resulting From Ingestion of “Molly” (3,4-Methylenedioxymethamphetamine)

Shelton, C. P., & Rosini, J. M. | Journal of Emergency Nursing | 1 September 2015

Ketamine abuse potential and use disorder

Liu, Y., Lin, D., Wu, B., & Zhou, W. | Brain research bulletin | 31 May 2016

Salvia divinorum: toxicological aspects and analysis in human biological specimens

Margalho, C., Corte-Real, F., López-Rivadulla, M., & Gallardo, E. | Bioanalysis | 9 June 2016

In reply – on the toxicity of ibogaine

Brunt, T. M., & Litjens, R. P. | Clinical toxicology | 31 May 2016

On the toxicity of ibogaine

Yip, L., & Deng, J. F. | Clinical Toxicology | 31 May 2016

Human Pharmacology of Mephedrone in Comparison to MDMA

Papaseit, E., Pérez-Mañá, C., Mateus, J. A., Pujadas, M., Fonseca, F., Torrens, M., ... & Farré, M. | Neuropsychopharmacology | 20 May 2016

Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue—Behavioural, pharmacokinetic and metabolic studies in the Wistar rat

Horsley, R. R., Lhotkova, E., Hajkova, K., Jurasek, B., Kuchar, M., & Palenicek, T. | Brain Research Bulletin | 4 May 2016

Anti-addiction Drug Ibogaine Prolongs the Action Potential in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Rubi, L., Eckert, D., Boehm, S., Hilber, K., & Koenig, X. | Cardiovascular Toxicology | 28 March 2016

Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models

Kyzar, E. J., & Kalueff, A. V. | Zebrafish | 22 March 2016

How toxic is ibogaine?

Litjens, R. P., & Brunt, T. M. | Clinical Toxicology | 25 January 2016

Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class

Dinger, J., Woods, C., Brandt, S. D., Meyer, M. R., & Maurer, H. H. | Toxicology Letters | 17 November 2015

“Herbal seizures” – atypical symptoms after ibogaine intoxication: a case report

Breuer, L., Kasper, B. S., Schwarze, B., Gschossmann, J. M., Kornhuber, J., & Müller, H. H. | Journal of medical case reports | 31 October 2015

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression

Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., & Nemeroff, C. B. | American Journal of Psychiatry | 29 June 2015

Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotria viridis) in female Wistar rat.

Pic-Taylor, A., da Motta, L. G., de Morais, J. A., Junior, W. M., Santos, A. D. F. A., Campos, L. A., ... & Caldas, E. D. | Behavioural processes | 3 June 2015

Ketamine-A Narrative Review of Its Uses in Medicine

Radvansky, B. M., Puri, S., Sifonios, A. N., Eloy, J. D., & Le, V. | American Journal of Therapeutics | Apr 24 2015

The hallucinogenic world of tryptamines: an updated review

Araújo, A. M., Carvalho, F., de Lourdes Bastos, M., de Pinho, P. G., & Carvalho, M. | Archives of toxicology | 16 April 2015

Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice

Zhuk, O., Jasicka-Misiak, I., Poliwoda, A., Kazakova, A., Godovan, V. V., Halama, M., & Wieczorek, P. P. | Toxins | 27 March 2015

Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers

Glue, P., Winter, H., Garbe, K., Jakobi, H., Lyudin, A., Lenagh‐Glue, Z., & Hung, C. T. | The Journal of Clinical Pharmacology | 4 February 2015

The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation

Koenig, X., & Hilber, K. | Molecules | 29 January 2015

Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans

Bouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., ... & Riba, J. | European Neuropsychopharmacology | 16 January 2015